30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

2Q13 Revenue: Biomet

(FY2013 ended 5/31/13; reporting is preliminary; company has not filed 10-Q)

$3,052.9MM, +9% (U.S. $1,862.2MM, +9%; Europe $710.2MM, +5%; International $480.5MM, +19%)

Reconstructive $1,696.3MM, +2%

  • Hips +2%
  • Knees +1%
  • Bone Cement/Other +2%

Sports/Extremities Trauma $600.1MM, +68%

  • SportsMed +8%
  • Extremities +20%
  • Trauma +259%

Spine/Bone Healing $291.3MM, -5%

  • Spine +1%
  • Bone Healing -21%

Dental $257.0MM, -2%

Other $208.2MM, +4%

  • Divested bracing business to Breg in February 2013
  • FY2014 launches include patient-specific tibial trays and posterior-stabilized thermal components, new Soft Anchor midway through fiscal year, expansion to ACL portfolio, bone-conserving comprehensive Nano shoulder in Europe

 

FY4Q13 revenue (reporting is preliminary; company has not filed 10-Q)

$783.9MM, +8% (U.S. $466.3MM, +6%; Europe $188.7MM, +5%; International $128.9MM, +17%)

Reconstructive $435.2MM, +1% (U.S. +1%)

  • Hips +2% (U.S. +2%)
  • Knees +0.1% (U.S. +0.1%)
  • Bone Cement/Other -1% (U.S. -3%)

Sports/Extremities Trauma $159.2MM, +65% (U.S. +56%)

  • SportsMed +1% (U.S. -4%)
  • Extremities +22% (U.S. +28%)
  • Trauma +267% (U.S. +249%)

Spine/Bone Healing $67MM, -18% (U.S. -19%)

  • Spine -8% (U.S. -8%)
  • Bone Healing -48% (U.S. -48%)

Dental $68.5MM, +0.2% (U.S. +2%)

Other $54MM, +7% (U.S. +2%)

Recon

  • Double-digit combined hip/knee growth in both Japan and China
  • Worldwide hip/knee pricing declined in low-single-digits
  • Continued rollout of Taperloc Complete hips, including full-length and microplasty short stem, plus XR 123 option featuring same stem geometry with 123-degree neck angle and shorter neck
  • Commenced limited ex-U.S. launch for Sirius double-tapered short hip stem for primary/revision
  • ~450 G7 next-gen multi-bearing acetabular cup procedures complete, to date
  • Launched SSK 360 in Japan, as well as Vanguard Select patient-specific femur
  • Noted increased market penetration for Signature total and partial knees and Orthosize digital x-ray templating software
  • Slight decline in global partial knees
  • Initiated U.S. direct-to-consumer T.V. ad supporting Oxford Partial Knee’s lifetime warranty

Cement/Other

  • Strong EMEA market demand for Optipac pre-filled cement mixing system
  • Received Japan regulatory approval for Cobalt cement, 1st entry into bone cement market there

Extremities

  • Extremities driven by comprehensive shoulder (includes primary, reverse, fracture and segmental revision options)
  • Initiated global launch of Access instrumentation for glenoid preparation, releasing 150 sets, with 100 additional slated for each month during 1HFY14

Trauma

  • Launched DVR Crosslock ePAK delivery system

Spine

  • Hardware impacted by mid-single-digit price decline
  • Introduced Translation pedicle screw with Polaris 5.5 Thoracolumbar spine system via limited clinical release

(Growth includes trauma acquisition and bracing divestiture)